Radiotherapy in oligometastatic prostate cancer—a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO)

Paul Rogowski1 · Christian Trapp1 · Rieke von Bestenbostel1 · Dinah Konnerth1 · Sebastian Marschner1 · Nina-Sophie Schmidt Hegemann1 · Claus Belka1,2 · Minglun Li1

Received: 14 November 2021 / Accepted: 2 March 2022 / Published online: 1 April 2022 © The Author(s) 2022

Abstract

Purpose Due to improved imaging, oligometastatic prostate cancer (OMPC) is diagnosed more frequently. Growing evidence shows that patients with a limited number of metastases benefit from primary-directed radiotherapy (PDT) as well as from metastasis-directed radiotherapy (MDT). This survey investigates the current treatment practice for OMPC among German-speaking radiation oncologists.

Methods Members of the German Society for Radiation Oncology (Deutsche Gesellschaft für Radioonkologie [DEGRO]) were surveyed regarding their current treatment practice via an anonymous online questionnaire sent by email. The survey included six general items and 14 specific items regarding treatment characteristics. Questionnaires with at least 50% of questions completed were considered for further analysis.

Results A total of 204 responses were received (15% response rate), 167 were considered for further analysis. Most respondents stated to be specialized in treating prostate cancer patients and to treat 10–30 patients with OMPC per annum; 97% considered PSMA-PET/CT necessary to define oligometastatic disease. Opinions differed regarding the use of systemic therapies: 63% of the respondents aimed to defer systemic therapy using radiotherapy in OMPC, whereas 37% considered systemic therapy necessary. In the setting of synchronous OMPC, 97% recommended PDT with or without a combination of MDT and/or systemic therapy. For metachronous nodal or bone oligometastatic recurrence, 98 and 99%, respectively, would opt for MDT. The majority would combine MDT with systemic therapy in patients with metachronous oligorecurrence. Respondents recommended normofractionation, hypofractionation, and SBRT for lymph node metastases in 49, 27, and 24%, respectively. No consensus existed regarding the field size for MDT of lymph node metastases. Most respondents preferred >5 fractions for treatment of bone metastases.

Conclusion Local radiotherapy for PDT and MDT is routinely used among respondents of this survey, representing 12% of all German-speaking radiation oncologists. The timing of systemic therapy, fractionation schedules, and field sizes are handled differently and remain an area of active investigation.

Keywords OMPC · Primary-directed therapy · Metastasis-directed therapy · ENRT · PSMA-PET/CT

Abbreviations

ADT Androgen deprivation therapy
ADT-FS Androgen deprivation therapy-free survival
BED3 Biological effective dose with an alpha/beta value of 3 Gy
CT Computed tomography
DEGRO Deutsche Gesellschaft für Radioonkologie e.V. (German Society for Radiation Oncology)
ENRT Elective nodal radiotherapy
EORTC European Organisation for Research and Treatment of Cancer

Availability of data and materials Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

1 Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
2 German Cancer Consortium (DKTK), Munich, Germany
Background

In 1995, Hellman and Weichselbaum introduced the term oligometastatic cancer for a state between localized and widespread disease, which is amenable to local treatment [1]. Sensitive PSA detection and improved imaging are increasingly leading to diagnosis of oligometastatic prostate cancer (OMPC) [2], and growing evidence shows that prostate cancer (PCa) patients with a limited number of metastases benefit from primary-directed therapy (PDT). In the randomized phase III Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial, local treatment of the primary improved overall survival in patients with a low metastatic burden [3]. Metastasis-directed therapy (MDT) is still a matter of debate. However, several phase II trials have reported favorable outcomes with MDT in OMPC. Palma and colleagues showed a survival benefit for stereotactic body radiotherapy (SBRT) to all metastatic lesions [4]. However, this study included patients across various histologies of which only 27% were PCa. The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) trial reported improved biochemical progression-free survival in the entire study population and prolonged distant metastasis-free survival in a subgroup of which only prostate-specific membrane antigen positive lesions were treated [5]. Moreover, Ost et al. investigated the deferral of androgen deprivation therapy (ADT) by MDT and established androgen deprivation therapy-free survival (ADT-FS) as a new endpoint [6]. MDT prolonged ADT-FS from 13 to 21 months compared to surveillance.

On the basis of data from the STAMPEDE trial, current national and international guidelines recommend PDT for patients with newly diagnosed OMPC additional to systemic treatment [7, 8]. The current German guideline states that MDT is not supported by sufficient evidence with regard to oncological outcomes but can be used to defer ADT and tumor progression. The European guideline recommends metastasis-directed therapy to metastatic PCa patients only within clinical trials or well-designed prospective cohort studies. Nevertheless, many vital questions in the treatment of OMPC are pending. In particular, the role of imaging methods, the relevance of the site of metastasis, combinations with systemic therapies, radiation fractionation schedules, and the optimal field size.

There is also growing evidence that different subcategories of oligometastasis should be distinguished [9, 10].

The purpose of this anonymous online survey was to investigate the current treatment practice for OMPC among German radiation oncologists.

### Table 1 Respondents and institutions characteristics

| Years of experience in radiooncology |
|--------------------------------------|
| < 5 years | 7.2% |
| 5–10 years | 12.0% |
| > 10 years | 80.8% |

| Type of facility |
|-----------------|
| Academic center (university hospital) | 22.2% |
| Nonacademic hospital | 21.6% |
| Private practice/ambulatory healthcare center | 56.3% |

| Specific expertise in treating PCa |
|----------------------------------|
| Yes | 77.8% |
| No | 12.6% |
| No answer | 9.6% |

| Are urooncological patients in your facility usually discussed in a multidisciplinary tumor board? |
|--------------------------------------------------|
| Yes | 79.6% |
| No | 20.4% |

| Number of OMPC patients treated per annum |
|------------------------------------------|
| < 10 | 28.1% |
| 10–30 | 57.5% |
| > 30 | 13.8% |
| No answer | 0.6% |

| Number of OMPC patients treated with PDT |
|----------------------------------------|
| < 10 | 43.7% |
| 10–30 | 42.5% |
| > 30 | 12.6% |
| No answer | 1.2% |

| Number of OMPC patients treated with MDT |
|----------------------------------------|
| < 10 | 29.9% |
| 10–30 | 52.1% |
| > 30 | 16.8% |
| No answer | 1.2% |
Table 2  Radiotherapy characteristics

| Which staging method do you consider necessary to define oligometastasis in PCa (multiple selection possible)? |
|--------------------------------------------------|
| Choline- or PSMA-PET/CT                              | 97.0% |
| CT of the thorax and abdomen                         | 29.9% |
| Bone scan                                          | 29.3% |
| MRI of the abdomen and pelvis                       | 28.1% |
| Whole-body MRI                                     | 4.8%  |

| How is oligometastasis defined in your facility? |
|--------------------------------------------------|
| 1 metastatic lesion                               | 1.8%  |
| ≤ 2 metastatic lesions                            | 3.6%  |
| ≤ 3 metastatic lesions                            | 34.1% |
| ≤ 4 metastatic lesions                            | 4.8%  |
| ≤ 5 metastatic lesions                            | 28.1% |

If a curative-intent therapy to all lesions is safely possible 25.7%

I do not believe that oligometastasis exists as a separate stage between localized and metastatic disease 1.2%

No answer 0.6%

Which of the following statements best corresponds to your opinion on systemic therapy for OMPC? 37.1%

Systemic therapy is always recommended for metastatic prostate cancer

Radiotherapy should aim to defer systemic therapy 62.9%

Which treatment would you recommend in a fit patient with synchronous oligometastasis and an untreated primary? 0%

Systemic treatment only 1.2%

PDT and systemic treatment 3.0%

MDT only 0.6%

MDT and systemic treatment 2.4%

PDT and MDT 29.3%

PDT and MDT and systemic treatment 63.5%

Which fractionation would you choose for PDT? 57.5%

Normofractionation 37.7%

Hypofractionation 4.8%

SBRT 4.8%

Does the indication for MDT differ in OMPC depending on whether it is distant lymph node metastases or bone metastases? 58.7%

Yes 58.7%

No 41.3%

Which treatment would you recommend in a fit patient with oligometastatic recurrence with bone metastases? 1.2%

Systemic treatment only 1.2%

MDT only 44.9%

MDT and systemic treatment 53.9%

Which fractionation do you prefer for MDT for bone metastases? 65.9%

<3 fractions 4.2%

3–5 fractions 29.9%

>5 fractions 65.9%

Table 2 (Continued)

| Which treatment would you recommend in a fit patient with oligometastatic recurrence with distant lymph node metastases (M1a)? |
|--------------------------------------------------|
| Systemic therapy only                            | 1.2%  |
| Metastasis-directed radiotherapy (MDT) only      | 37.7% |
| MDT + systemic therapy                           | 60.5% |
| No answer                                        | 0.6%  |

| Which fractionation would you prefer for MDT for distant lymph node metastases (M1a)? |
|--------------------------------------------------|
| Normofractionation                                | 49.1% |
| Hypofractionation                                 | 26.9% |
| SBRT                                             | 24.0% |

| Which field size would you prefer for MDT for distant lymph node metastases (M1a)? |
|--------------------------------------------------|
| Focal irradiation of the affected lymph node (involved-node radiotherapy) 33.5% |
| Irradiation of the affected lymph node region (involved-field radiotherapy) 22.8% |
| Irradiation of the affected and adjacent lymph node regions (elective nodal radiotherapy) 29.9% |
| Additional inclusion of the entire pelvic lymphatic drainage area (whole-pelvic radiotherapy) 13.2% |
| No answer                                        | 0.6%  |

Do you differentiate in the treatment with MDT between synchronous and metachronous oligometastatic disease? 43.1%

Yes 43.1%

No 56.3%

No answer 0.6%

Which of these factors do you consider relevant for the decision for or against radiotherapy for oligometastatic prostate cancer (multiple selection possible)? 61.7%

Age 61.7%

Number of metastases 98.8%

Gleason Score 45.5%

Initial PSA 25.1%

PSA before radiotherapy 38.3%

PSA doubling time 61.1%

Hormone sensitivity 57.5%

CT computed tomography, MDT metastasis-directed therapy, MRI magnetic resonance imaging, PCa prostate cancer, PDT primary-directed therapy, PSA prostate specific antigen, PSMA-PET/CT prostate specific membrane antigen positron-emission tomography/computed tomography, SBRT stereotactic body radiotherapy

Methods

An anonymous, web-based survey was developed with the online survey tool LimeSurvey (LimeSurvey GmbH, Hamburg, Germany) licensed for use by the Ludwig Maximilian University of Munich. The survey contained 6 questions regarding respondent and institution characteristics and 14 specific questions regarding radiotherapy practice for OMPC (Tables 1 and 2). Participants were instructed
to choose answers from a multiple-choice questionnaire allowing for one or, in some cases, multiple answers. A link to the questionnaire was sent via email to approximately 1361 radiation oncologists compiled through the Deutsche Gesellschaft für Radioonkologie e.V. (DEGRO) directory, the official German Society for Radiation Oncologists.

The email invitation containing rationale, instructions on participation and contact information was sent out on May 19, 2021, with a reminder ensuing on June 9, 2021, to maximize response rate. Responses were collected from May to July 2021. Because the questionnaire allowed to skip single or multiple questions without answering, only those questionnaires with at least 50% of the questions answered were eligible for analysis using descriptive statistics. Ethical approval for a pattern of care study comprising an anonymous online questionnaire was not applicable.

Results

A total of 204 responses were received (15% response rate). Of these, 167 respondents (81.4%) had answered at least 50% of the questions, and these questionnaires were hence considered for further analysis. Characteristics of the respondents and institutions are summarized in Table 1. Most respondents were experienced radiation oncologists with more than 10 years of experience (80.8%) and had specific expertise in treating PCa (77.8%). Respondents worked in public academic facilities, nonacademic facilities, and private practices in 22.2, 21.6, and 56.3%, respectively. The majority of respondents reported to treat <10 patients annually with PDT (43.7%) and 10–30 patients with MDT (52.1%).

Table 2 shows the 14 items addressing treatment characteristics and associated responses. The large majority of respondents (97.0%) deemed staging with PSMA-PET/CT necessary for definition of oligometastatic disease. Oligometastatic disease was most often defined by the respondents as ≤3 (34.1%) and ≤5 metastatic lesions (28.1%), and as a disease state with the possibility to safely treat all lesions with curative-intent therapy (25.7%). Opinions differed with regard to systemic therapy: 62.9% of respondents answered that radiotherapy should aim to defer systemic therapy in OMPC, whereas 37.1% considered systemic therapy to always be necessary in metastatic disease. Nevertheless, most respondents recommended PDT plus MDT and systemic therapy for a fit patient with synchronous oligometastasis and an untreated primary (63.5%). PDT with or without a combination of MDT and/or systemic therapy was recommended in this case by 97.0% of respondents. None of the respondents opted for systemic therapy only in this setting. Normofractionation, hypofractionation, and SBRT for PDT would have been chosen by 57.5, 37.7, and 4.8%, respectively.

With regard to the indication for MDT, most of the respondents did not distinguish between synchronous and metachronous oligometastatic disease (56.3%) but made a distinction between distant lymph node metastases and bone metastases (58.7%). In case of a fit patient with bone oligorecurrence, 53.9% recommended MDT with systemic therapy and 44.9% recommended MDT only. In case of distant lymph node oligorecurrence, MDT with and without systemic therapy was recommended by 60.5 and 37.7%, respectively. Most respondents would choose a fractionation scheme with ≥5 fractions for MDT for bone metastases (65.9%). For MDT of distant lymph node oligorecurrence, 49.1% of respondents would offer normofractionated radiotherapy, 26.9% hypofractionated radiotherapy, and 24.0% stereotactic body radiotherapy (SBRT). Regarding the field size for MDT in the case of distant lymph node oligorecurrence, most respondents recommended involved-node radiotherapy (INRT; 33.5%), followed by elective nodal radiotherapy (ENRT; 29.9%), involved-field radiotherapy (IFRT; 22.8%), and additional inclusion of the entire pelvic lymphatic drainage area (whole-pelvic radiotherapy; 13.2%).

The parameters considered by respondents as most relevant for the decision for radiotherapy in OMPC were number of metastases (98.8%), age (61.7%), prostate-specific antigen (PSA) doubling time (61.1%), and hormone sensitivity (57.5%). Gleason score (45.5%), PSA value before radiotherapy (45.5%), PSA value before radiotherapy (38.3%), and initial PSA value (25.1%) were considered less important.

Discussion

While OMPC is recognized as a special oncologic setting with a growing body of encouraging evidence for effective local treatment of primary and metastases, the answers to many vital questions are still pending [11]. Nevertheless, local therapies have found their way into the clinical practice of radiation oncologists. Therefore, this survey aimed to highlight the treating practice for OMPC among DEGRO members. The majority of respondents declared in the questionnaire to have more than 10 years of experience and to be specialized in the treatment of PCa. As expected, the respondents came from academic and nonacademic hospitals and approximately half of them claimed to work in private practices.

Staging with PSMA-PET/CT is increasingly applied in primary and recurrent PCa and has been shown to outperform every other imaging technique [12, 13]. Accordingly, the vast majority of respondents of this survey considered choline- or PSMA-PET/CT as necessary to define
oligometastatic disease over any other imaging modality. However, the definition of OMPC in the literature is inconsistent, and it is thus not surprising that respondents defined OMPC with different numerical cutoffs ranging from one to five metastases. The STAMPEDE trial showed that prostate radiotherapy improved survival in patients with low but not with high metastatic burden (defined according to ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) criteria) [3, 14]. Furthermore, in a secondary analysis by Ali and colleagues, the benefit of PDT was greater in patients with nonregional lymph nodes (M1a) or up to three bone metastases than among patients with four or more bone metastases or visceral metastases [15]. Of note, in the STAMPEDE trial, metastatic burden was assessed with bone scans, MRI, and CT, which have been shown to have lower detection rates than PSMA-PET/CT. Therefore, patients with an even higher metastatic burden in PSMA-PET/CT might also benefit from local treatment, making a strict numerical cutoff difficult. Noteworthily, a relevant proportion of respondents of this survey defined oligometastatic disease as a disease state in which a curative-intent treatment to all metastases is possible. This might be a reasonable approach as long as there is neither a precise numerical definition nor molecular markers for the oligometastatic state in PCa.

In metastatic hormone-sensitive PCa, androgen deprivation therapy in combination with novel hormonal agents like abiraterone, enzalutamide, and apalutamide or chemotherapy with docetaxel is the standard of care. However, these therapies can be associated with adverse effects and a deterioration in quality of life. In this survey, two thirds of respondents agreed that the aim of radiotherapy in oligometastatic disease should be to delay systemic therapy, probably owing to evidence from trials investigating a controversial approach of using local therapies in OMPC to defer systemic therapy [5, 6]. Remarkably and partially in contrast to the previous statement, in the given setting with synchronous OMPC, 69% of the respondents in this survey favored a combination of systemic therapy and local radiotherapy. In the setting of metachronous nodal or bone oligometastatic recurrence, still 61 and 54%, respectively, would opt for a combination with systemic therapy. Nevertheless, the approach using local radiotherapies in OMPC to defer systemic therapy should be used with caution since subclinical disease is missed by imaging in a significant proportion of oligometastatic patients and delaying systemic therapy may therefore reduce long-term tumor control. Indeed, also the majority of panelists of the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 voted for adding MDT to systemic therapies, instead of it replacing them [16].

Our findings show that the optimal dose schedule and the optimal field size for radiotherapy in OMPC remain controversial. For PDT, the majority of respondents in the survey would recommend a normofractionated (58%) or hypofractionated treatment (38%). No precise cutoff values for hypofractionation and SBRT (which is commonly used synonymously with ultrahypofractionation) were provided in the questionnaire. Typically, doses between 2.2 Gy and 4 Gy are regarded as hypofractionated and doses of 4 Gy and beyond as ultrahypofractionated [17]. The best evidence exists for the two schedules used in the STAMPEDE trial (55 Gy in 20 fractions over 4 weeks or 36 Gy in 6 fractions over 6 weeks). Of note, a prespecified analysis found heterogeneity in the effect on failure-free survival by the two fractionation schemes. While the daily schedule led to a clear advantage in failure-free survival, the effect in patients with the weekly schedule was less pronounced. However, in designing the STAMPEDE trial, less burdensome concepts compared to conventional fractionation schedules for definitive prostate radiotherapy were intentionally chosen for metastatic disease. Thus, radiotherapy with sufficient dose, normofractionated or hypofractionated, may further improve oncological outcomes.

With regard to MDT, the heterogeneity of radiotherapeutic approaches is even greater. First, a distinction can be made between distant lymph node and bone metastases, as the prognosis in lymph node-positive PCa has proved to be superior [18, 19]. In this survey, 59% of respondents stated that their indication for radiotherapy depended on whether it was distant lymph node or bone oligometastatic disease. Due to the rarity of occurrence, other sites of distant metastasis were not included in the questionnaire. Although so far there is no grade 3 evidence for MDT, almost 99% of respondents in this survey recommended MDT in both settings. Furthermore, more respondents opted for a combination with systemic therapy in the case of lymph node metastases compared to bone metastases (61 vs. 54%). Systemic therapy alone was recommended only by 1.2%.

For MDT of lymph node metastases, several approaches have been suggested, ranging from focal INRT with SBRT to IFRT, ENRT, and whole-pelvis radiotherapy [20–22]. Our results show that the optimal field size is still very controversial and that each of these approaches are favored by a relevant number of respondents. In the literature, SBRT and ENRT were directly compared in a large retrospective analysis by De Bleser and colleagues. They analyzed 506 patients with nodal oligorecurrence staged mostly by choline PET/CT and treated by either ENRT (with or without SIB) or SBRT. Patients had a significantly improved 3-year metastasis-free survival of 77% when treated with ENRT compared to 68% after SBRT. However, early and late toxicity was higher in the ENRT group [23]. Lepinoy et al. retrospectively compared IFRT, mostly using 36 Gy
in 5 fractions, to conventionally fractionated whole-pelvis radiotherapy. Again, the use of extended fields was associated with a significantly longer failure-free time, albeit at the cost of more acute gastrointestinal toxicity [24]. Of note, survival data are still lacking.

Regarding the treatment of bone oligometastases, respondents favored various fractionation schedules ranging from SBRT in one or two fractions to regimens with more than five fractions. This reflects the ongoing debate in the literature regarding the best dose concepts in bone OMPC [25]. Retrospective data have suggested better oncological outcomes with BED3 > 100 Gy [26, 27]. However, series with lower BED3 reported very good local control rates as well [10].

Recently, a European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) consensus recommendation suggested a classification of oligometastatic disease with the goal to better differentiate between various subcategories, i.e., synchronous and metachronous disease [28]. Also, the majority of panelists of APCCC considered it important to distinguish between these two categories [16]. In our survey, 56% of the respondents stated to make no distinction between synchronous and metachronous OMPC. This may be due to the inconsistent data in the literature. While some retrospective data show better oncological outcomes in synchronous OMPC compared to metachronous disease, other studies report contradicting results [10, 24, 29, 30].

The major limitation of our study is the low response rate of 15%, with a sample size of 167 responses considered for analysis. Moreover, the nature of surveys itself can lead to biases because respondents might describe what they would like to see in daily professional work in their answers, rather than the answers mirroring current practice in the respective institution. Selection bias could not be avoided, as more interested radiation oncologists were more likely to participate in this survey. Furthermore, respondents might tend to use radiotherapy in OMPC more often than the majority of the nonrespondents. Thus, our findings have to be interpreted with caution, as they may not be representative of other colleagues who chose not to participate. Nevertheless, to the best of our knowledge, the study represents the first survey among German radiation oncologists on this important issue. We believe our survey has added important insight into the treatment practice of OMPC and may serve as a basis for future prospective studies. An overview of open questions to be addressed in future clinical trials is presented in Table 3.

**Table 3** Overview of open questions to be addressed in future clinical trials

| Question                                                                 | Response |
|--------------------------------------------------------------------------|----------|
| What is the optimal systemic therapy in combination with PDT for synchronous OMPC? |          |
| What is the recommended field size for PDT (inclusion of pelvic RT for N1 OMPC)? |          |
| What is the optimal fractionation schedule for PDT?                     |          |
| What is the effect of MDT to all lesions in synchronous OMPC (in addition to PDT and systemic therapy)? |          |
| Does MDT provide an OS benefit in OMPC?                                 |          |
| Can MDT defer systemic therapy without compromising OS?                 |          |
| What is the optimal fractionation schedule for MDT?                     |          |
| What is the optimal field size for MDT of lymph node metastases?        |          |

**Abbreviations**

MDT: metastasis-directed therapy; OMPC: oligometastatic prostate cancer; OS: overall survival; PDT: primary-directed therapy; RT: radiotherapy

**Conclusion**

This survey provides real-life data on the pattern of care for OMPC among German radiation oncologists. Radiotherapy for PDT and MDT is routinely used among respondents, representing 12% of all German-speaking radiation oncologists. The timing of systemic therapy, fractionation schedules, and field sizes are handled differently and remain an area of active investigation. Prospective trials are warranted to investigate the optimal treatment strategy for OMPC.

**Funding** No funding was received.

**Author Contribution** Conceptualization: PR and ML; methodology: CT, DK, and SM; writing—original draft preparation: PR; writing—review and editing: RvB, CT, DK, and ML; supervision: NSH, ML, and CB.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** P. Rogowski, C. Trapp, R. von Bestenbostel, D. Konnerth, S. Marschner, N.-S. Schmidt Hegemann, C. Belka, and M. Li declare that they have no competing interests.

**Ethical standards** For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8. PMID: 7799047

2. Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective. An ESTRO-ASTRO consensus document. Radiother Oncol 148: 157–166. https://doi.org/10.1016/j.radonc.2020.04.003

3. Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

4. Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818

5. Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147

6. Ost P, Reynders D, Decaestecker K et al (2017) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer re-recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):JCO.2017.75.485. https://doi.org/10.1200/JCO.2017.75.4853

7. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe) A. (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakazinom/`. Accessed 11 Sept 2021

8. Mottet N, Bellmunt J, Briers E et al (2021) EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4. Eur Assoc Urol. www.uroweb.org/gls/pockets/english/07_Prostate_Cancer.pdf. Accessed 27.04.2021

9. Deek MP, Van der Eecken K, Phillips R et al (2021) The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol. https://doi.org/10.1016/j.euro.2020.12.040

10. Rogowski P, Trapp C, von Bestenbostel R et al (2021) Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol 16(1):1–11. https://doi.org/10.1186/s13041-021-01849-8

11. Rogowski P, Roach M, Schmidt-Hegemann NS et al (2021) Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 16(1):1–16. https://doi.org/10.1186/s13041-021-01776-8

12. Fendler WP, Eiber M, Behrshiti M et al (2017) 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014–1024. https://doi.org/10.1007/s00259-017-3670-z

13. Lapa C, Nestle U, Albert NL et al (2021) Value of PET imaging for radiation therapy. Strahlenther Onkol. https://doi.org/10.1007/s00066-021-01812-2

14. Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/nejmoa1503747

15. Ali A, Hoyle A, Haran ÁM et al (2021) Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 7(4):555–563. https://doi.org/10.1001/jamaoncol.2020.7857

16. Gillessen S, Attard G, Beer TM et al (2020) Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019[formula presented]. Eur Urol 77(4):508–547. https://doi.org/10.1016/j.eururo.2020.01.012

17. Wolf F, Seldmayer F, Aebersold D et al (2021) Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 197(2):89–96. https://doi.org/10.1007/s00066-020-01723-8

18. Halabi S, Kelly WK, Ma H et al (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34(14):1652–1659. https://doi.org/10.1200/JCO.2015.65.7270

19. Gandaglia G, Karakiewicz P, Briganti A et al (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68(2):325–334. https://doi.org/10.1016/j.euro.2014.07.020

20. Nicosia L, Franzese C, Mazzola R et al (2020) Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol 196(3):213–221. https://doi.org/10.1007/s00066-019-01523-9

21. Pinkawa M, Aebersold D, Böhmer D et al (2021) Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol 197(7):575–580. https://doi.org/10.1007/s00066-021-01778-1

22. Carrasquilla M, Creswell ML, Pepin AN et al (2021) Rationale for involved field stereotactic body radiation therapy-enhanced intermittent androgen deprivation therapy in hormone-sensitive nodal oligo-recurrent prostate cancer following prostate Stereotactic body radiation therapy. Front Oncol 10:1–9. https://doi.org/10.3389/fonc.2020.606260

23. De Bleser E, Jereczek-fossa BA, Pasquier D et al (2019) Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of Stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. https://doi.org/10.1016/j.euro.2019.07.009

24. Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, Cochet A, Créhange G (2019) Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging 46(1):40–48. https://doi.org/10.1007/s00259-018-4159-0. Epub 2018 Sep 28. PMID: 30267117

25. Zeng KL, Tseng CL, Soliman H, Weiss Y, Sahgal A, Myrehaug S (2019) Stereotactic body radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol 9:1–11. https://doi.org/10.3389/fonc.2019.00337

26. Ost P, Jereczek-Fossa BA, Van As N et al (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naïve recurrence: a multi-institutional analysis. Eur Urol 69(1):9–12. https://doi.org/10.1016/j.euro.2015.07.004

27. Hurmuz P, Oral C, Ozyigit G et al (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol. https://doi.org/10.1007/s00066-020-01660-6

28. Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/s1470-2045(20)30094-8

29. Ong WL, Koh TL, Joon LD et al (2019) Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiother-
apy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. BJU Int. https://doi.org/10.1111/bju.14886

30. Kalinauskaite G, Senger C, Kluge A et al (2020) 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. PLoS ONE 15(10):e240892. https://doi.org/10.1371/journal.pone.0240892